Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

LBBAP Versus ILR in Patients With New-Onset LBBB and Moderately Reduced LVEF After TAVI (LBB(AP)TAVI)

13 november 2026 bijgewerkt door: University Hospital, Clermont-Ferrand

Comparison of Left Bundle Branch Area Pacing (LBB(AP)) and Implantable Loop Recorder (ILR) in Patients With New-onset Left Bundle Branch Block and Moderately Reduced LVEF After Transcatheter Aortic Valve Implantation (TAVI): A Randomized Multicenter Study.

Patients with new-onset complete LBBB (QRS > 120 ms, persisting > 24 h after TAVI) and moderately reduced LVEF (35-50%) will be screened in participating centers.

Eligible patients will be centrally randomized 1:1 (stratified by center and atrial fibrillation (yes/no)) to either:

  • Experimental arm: Left bundle branch area pacing (LBB(AP)) with Biotronik pacemaker and dedicated conduction system pacing leads.
  • Control arm: Implantable loop recorder (ILR, Biotronik BIOMONITOR IV) for rhythm monitoring.

The occurrence of the following events within 12 months of randomization will be evaluated: hospitalization for heart failure, syncope or hemodynamically significant dizziness, or high-grade atrioventricular conduction disturbance.

The impact of LBB(AP) compared to ILR monitoring will be evaluated at 6, 12, 24, and 36 months regarding: incidence of atrial fibrillation; incidence of non-sustained ventricular tachycardia; evolution of left ventricular ejection fraction; quality of life; hospitalizations; mortality; medico-economic outcomes; qccurrence of high-grade AV conduction disorders beyond 12 months; omplications related to pacemaker or ILR implantation; unscheduled pacemaker implantation in the ILR group.

Patients will be monitored following a regular schedule that includes clinical visits, transthoracic echocardiography , ECG, remote device monitoring, and EQ-5D at 6, 12, 24 and 36 months.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

700

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Angers, Frankrijk, 49000
        • CHU d'Angers
        • Hoofdonderzoeker:
          • Antoine POIRIER
      • Clermont-Ferrand, Frankrijk, 63000
      • Dijon, Frankrijk, 21000
        • CHU de DIJON
        • Hoofdonderzoeker:
          • Fabien GARNIER

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Patients with new-onset complete left bundle branch block (LBBB) defined as QRS duration >120 ms, occurring after TAVI and persisting for >24 hours on ECG. New-onset complete LBBB will be confirmed by QRS duration >120 ms together with standard morphological criteria (broad, notched or slurred R waves in leads I, aVL, V5 and V6, with absence of Q waves in V5-V6), assessed by the site cardiologist and confirmed by the adjudication committee, in line with current ESC and ACC/AHA/HRS recommendations.
  2. Left ventricular ejection fraction (LVEF) between 35% and 50%, assessed within one month before TAVI, in a stable hemodynamic state.
  3. Patients implanted with a self-expanding or balloon-expandable valve.
  4. Age ≥ 18 years.
  5. TAVI procedure performed according to current ESC guidelines. The applicable reference is the 2025 ESC/EACTS Guidelines for the management of valvular heart disease (Praz, et al. Eur Heart J. (2025) 46, 4635-4736), or any subsequent official ESC update in force at the time of each patient's procedure.
  6. Life expectancy > 1 year.
  7. Affiliation to a social security scheme
  8. Written informed consent provided before study enrollment.

Exclusion Criteria:

  1. Permanent pacemaker implantation (PPI) before TAVI.
  2. Complete atrioventricular block after TAVI leading to immediate PPI.
  3. Permanent pacemaker implantation after TAVI for another indication (non-protocol).
  4. Pre-existing LBBB before TAVI.
  5. Trans-venous permanent pacemaker implantation: No superior vena cava access or mechanical tricuspid valve.
  6. Pregnancy or breastfeeding.
  7. No affiliation to a social security scheme.
  8. Refusal to participate or withdrawal of informed consent.
  9. Incapacity to consent.
  10. Adults under legal protection (trusteeship, guardianship, curatorship).

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Left bundle branch area pacing with pacemaker and conduction system pacing (AMVIA SKY DR-T device)

LBB(AP) procedure will be performed by experienced operators according international guidelines and expert consensus. The implantation technique will be those used routinely in these expert centers.

The procedure will begin with a vein access (axillary, sub-clavian or cephalic). The atrial, if necessary, will be implanted as usual practice. LBB(AP) lead will be implanted as recommended. LBB(AP) positioning criteria, as described in reference clinical studies, will be checked in order to differentiate between LBB(AP) and deep septal pacing.

Ander: Implantable loop recorder for rhythm monitoring (ILR, Biotronik BIOMONITOR IV Device)

Control arm

ILR Procedure will be performed by experienced operators according international guidelines and expert consensus. The implantation technique will be those used routinely in these expert centers.

The implanted device will be a Biomonitor IV (Biotronik, Berlin, Germany) and next generation if necessary.

The implantable Loop Recorder is a single-lead ECG monitor of small size with long-term functionality (approximately 3 to 5 years). It is implanted under local anesthesia in the subcutaneous space of the left thoracic region (incision at the level of the 4th left intercostal space at a 45° angle).

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The first occurrence of one of the following events : hospitalization for worsening heart failure, episode of syncope or dizziness, high-grade atrioventricular conduction disturbance)
Tijdsspanne: From randomization to 12 follow up

The primary efficacy endpoint is a composite clinical outcome evaluated at 12 months after randomization, defined as the first occurrence of one of the following events:

  1. Hospitalization for worsening heart failure,
  2. Episode of syncope or dizziness,
  3. High-grade atrioventricular conduction disturbance (second-degree AV block type II or third-degree AV block requiring implantation of a permanent pacemaker, documented > 3 seconds on ILR or ECG)).

The composite endpoint will be analyzed as time-to-event data with death considered as a competing risk.

From randomization to 12 follow up

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of atrial fibrillation, ventricular tachycardia, non-sustained ventricular tachycardia
Tijdsspanne: At 6,12, 24 and 36 months after randomization
At 6,12, 24 and 36 months after randomization
Evolution of LVEF
Tijdsspanne: At 6,12, 24 and 36 months after randomization

Measurement of LVEF at inclusion and at each follow-up time point. The change in LVEF over time will be assessed relative to the date of inclusion and the preceding time point.

At 6,12, 24 and 36 months after randomization
Evolution of Quality of life (EQ-5D)
Tijdsspanne: At 6, 12, 24 and 36 months after randomization

Measurement of EQ-5D at inclusion and at each follow-up time point. The change in EQ-5D over time will be assessed relative to the date of inclusion and the preceding time point.

At 6, 12, 24 and 36 months after randomization
Incidence of Hospitalizations (all-cause, cardiovascular, HF-related)
Tijdsspanne: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization
Incidence of Mortality (all-cause, cardiovascular, HF-related)
Tijdsspanne: At 6, 12, 24 and 36 months after randomization

Measurement of the cumulative incidence of all-cause, cardiovascular, and heart failure-related mortality at 6, 12, 24, and 36 months after randomization, based on the occurrence and documented cause of death.

At 6, 12, 24 and 36 months after randomization
Medico-economic evaluation
Tijdsspanne: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization
Complications related to pacemaker or ILR implantation
Tijdsspanne: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization
Unscheduled pacemaker implantation in the ILR group
Tijdsspanne: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

15 oktober 2026

Primaire voltooiing (Geschat)

15 oktober 2033

Studie voltooiing (Geschat)

15 oktober 2034

Studieregistratiedata

Eerst ingediend

6 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

26 oktober 2026

Eerst geplaatst (Werkelijk)

2 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

13 november 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren